The AR is the most prevalent sex steroid receptor occurring in up to 90% of all breast cancers (in situ and invasive disease including early and metastatic setting) [2,3,4] and in a lower rate in TNBC (0%–53%) [5,6]. Here, AR is linked to breast cancer.